Stock Events

Stock Events

AtaiBeckley 

$4
373
-$0.2-4.76% Tuesday 20:00

Statistics

Day High
4.23
Day Low
3.95
52W High
6.45
52W Low
1.38
Volume
4,550,394
Avg. Volume
-
Mkt Cap
961.75M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

20MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-1.73
-1.19
-0.65
-0.1
Expected EPS
-0.108786
Actual EPS
N/A

Financials

-48,463.96%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
616,000Revenue
-298.54MNet Income

Analyst Ratings

16.33Average Price Target
The highest estimate is 25.00.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ATAI. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Compass Pathways
CMPS
Mkt Cap1.22B
Compass Pathways operates in the psychedelic medicine space, directly competing with ATAI in developing therapies for mental health conditions.
GH Research
GHRS
Mkt Cap1.42B
GH Research is involved in the development of therapeutics for psychiatric and neurological disorders, overlapping with ATAI's mission and market.
Nuveen Municipal Income
NUMI
Mkt Cap0
Numinus Wellness operates in the space of psychedelic therapy development, making it a competitor to ATAI in the mental health treatment sector.
Revive Therapeutics
RVVTF
Mkt Cap11.33M
Revive Therapeutics focuses on the research and development of psychedelic and cannabinoid-based therapeutics, competing with ATAI in the broader alternative medicine market.
Johnson & Johnson
JNJ
Mkt Cap546.9B
Johnson & Johnson, through its subsidiary Janssen Pharmaceuticals, has developed a ketamine-based nasal spray for depression, indirectly competing with ATAI's broader focus on mental health treatments.

About

Atai Beckley NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Amstelveen, Netherlands.
Show more...
CEO
Mr. Christian Angermayer
Employees
54
Country
United States
ISIN
US04650F1012

Listings

MU
DE
B72.MU
MU
DE
9VC.MU
STU
DE
B72.STU
XNAS
US
ATAI

0 Comments

Share your thoughts

FAQ

What is AtaiBeckley stock price today?▼
The current price of ATAI is $4 USD — it has decreased by -4.76% in the past 24 hours. Watch AtaiBeckley stock price performance more closely on the chart.
What is AtaiBeckley stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange AtaiBeckley stocks are traded under the ticker ATAI.
Is AtaiBeckley stock price growing?▼
ATAI stock has fallen by -2.91% compared to the previous week, the month change is a +3.9% rise, over the last year AtaiBeckley has showed a +189.86% increase.
What is AtaiBeckley market cap?▼
Today AtaiBeckley has the market capitalization of 961.75M
When is the next AtaiBeckley earnings date?▼
AtaiBeckley is going to release the next earnings report on May 20, 2026.
What were AtaiBeckley earnings last quarter?▼
ATAI earnings for the last quarter are -1.73 USD per share, whereas the estimation was -0.1 USD resulting in a -1,558.82% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is AtaiBeckley revenue for the last year?▼
AtaiBeckley revenue for the last year amounts to 616,000 USD.
What is AtaiBeckley net income for the last year?▼
ATAI net income for the last year is -298.54M USD.
How many employees does AtaiBeckley have?▼
As of May 06, 2026, the company has 54 employees.
In which sector is AtaiBeckley located?▼
AtaiBeckley operates in the Health & Wellness sector.
When did AtaiBeckley complete a stock split?▼
AtaiBeckley has not had any recent stock splits.
Where is AtaiBeckley headquartered?▼
AtaiBeckley is headquartered in New York, United States.